搜索
Search
img

News Center

新闻中心

Kintor Pharmaceutical Enters Loncar China BioPharma Index after 100 Days of Listing in HK

Kintor Pharmaceutical Enters Loncar China BioPharma Index after 100 Days of Listing in HK

(Summary description)In August 2020, the Loncar China BioPharma Index underwent its six-monthly adjustments and restructuring, adding 14 biopharmaceutical companies, including Kintor Pharmaceutical Limited (stock code: 9939.HK).

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2020-09-01 18:38
  • Views:
Information

In August 2020, the Loncar China BioPharma Index underwent its six-monthly adjustments and restructuring, adding 14 biopharmaceutical companies, including Kintor Pharmaceutical Limited (stock code: 9939.HK).

 

The following is extracted from a special report from DrugTimes: Probably impacted by the COVID-19 pandemic, there has been an investment and financing frenzy in the healthcare field in 2020, where biotechnological companies, both domestic and overseas, are quite popular in the capital market. As domestic biotechnological companies developed and successively launched their IPOs with enthusiastic market response, changes emerged to a highly representative stock index.

 

On 10 August 2020,the Loncar China BioPharma Index underwent its six-monthly adjustments and restructuring, newly adding 14 biopharmaceutical enterprises.

 

List of 14 Newly Added Companies

 

The Loncar China BioPharma ETF (NASDAQ: CHNA) was established by renowned investment institution Loncar Investments, and was officially rolled out in the NASDAQ on 15 August 2018.

 

At first, the index included 28 Chinese pharmaceutical companies, simultaneously tracking the development of China’s biopharmaceutical industry both domestically and abroad.

28 Chinese Biopharmaceutical Companies in Newly Launched CHNA On 26 April 2019, eight months after the CHNA became available, Mr Brad Loncar, CEO of Loncar Investments, released an article entitled “Reflections on a Recent Trip to Asia”, where he discussed in detail his views on China’s biotechnology and R&D for new drugs (relevant reading: Wall Street Investment Guru’s Views on China’s Biotechnology and R&D for New Drugs). Two years after the HKEX introduced its new listing system, this guru commended Hong Kong’s biotechnological market for its changes and size.

 

Potentially in view of the development and massiveness of the biotechnological market and companies, Mr Brad Loncar has expressed the following viewpoint on the CHNA’s restructuring: “I believe the powerful and innovative biotechnological industry will become a key part of China’s new economy, and this foundation has been laid.”

 

Companies entering the CHNA are all key players in China’s biotechnological field, covering the largest companies in the pharmaceutical industry, innovation-driven new biotechnological stars, open CRO/CMO, diagnostic companies and the like. They are all listed firms on the Hong Kong Stock Exchange or NASDAQ and meet the following three requirements: firstly, they are an innovator or leader in China’s biopharmaceutical industry; secondly, they are rooted in China or have a significant proportion of their business in China; thirdly, they reach a certain level in financial scale.

 

Most of the 14 newly added biopharmaceutical companies are technical innovative pharmaceutical R&D firms. They have strong R&D capabilities, a large number of R&D pipelines and leading clinical progress, covering tumour gene sequencing and precision medicine, antibody drugs, small molecule targeted inhibitors, tumour cell immunotherapy and other technologically advanced fields.

 

Latest Composition of Loncar China BioPharma Index

Related documents

There is currently no content to display
Please add data record on website background.